Access Pharmaceuticals Inc. (ACCP.OB) – Always Developing
When it comes to the war on cancer and its side effects, Access Pharmaceuticals is taking a proactive stance. This Dallas, Texas based biopharmaceutical company develops and brings to market proprietary products for the treatment and supportive care of those with cancer. They trade through the OTCBB and have a market capitalization of $5.1M. Access, as an emerging drug manufacturer, has a product called ProLindac(TM) which is in Phase II clinical testing. This drug is in development for patients with ovarian cancer. With this product, Access seeks ways to deliver a powerful and cytotoxic platinum drug to tumors, while protecting…